Adult Type 2 Diabetes
A Study of LY3209590 in Participants With Type 2 Diabetes Mellitus
The reason for this study is to see if the study drug LY3209590 is safe and effective in participants with type 2 diabetes that have already been treated with basal insulin.
The study will last about 39 weeks and may include up to 23 visits.
Key Participation Requirements
All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria
Participant must have type 2 diabetes mellitus (T2DM) treated with basal insulin and up to 3 of the following oral antihyperglycemic medication (OAM): • DPP-4 inhibitors • SGLT-2 inhibitors • biguanides • alpha-glucosidase inhibitors • sulfonlyureas
Participant must not have type 1 diabetes mellitus or latent autoimmune diabetes
Participant must not have any episodes of severe hypoglycemia and/or hypoglycemia unawareness within the 6 months prior to screening
Participant must not have had a heart attack or stroke in the past 2 months or have heart failure that significantly limits their physical activity
Participant must not have acute or chronic hepatitis, or obvious clinical signs or symptoms of any other liver disease
Participant must not have active or untreated cancer
Participant must not have had Chronic (>14 days) systemic glucocorticoid therapy